Valneva announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Toggle Navigation
- Research
Back - VBCFBack
- CompaniesBack
- Companies at Vienna BioCenter
- Biotech CompaniesBiotech CompaniesOpen SubmenuBack
- a:head
- Ablevia Biotech
- ACCANIS Biotech
- ADvantage Therapeutics
- Aelian Biotechnology
- Affiris
- Akribes
- Apeiron Biologics
- Ares Genetics
- Austrianni
- BioNTech R&D Austria
- Bird-C
- bit.bio discovery GmbH
- CALYXHA Biotechnologies
- ChanPharm
- EUCODIS Bioscience
- Eveliqure
- Evercyte
- Exscientia
- G.ST Antivirals
- Haplogen
- Hookipa Pharma
- JLP Health
- Lexogen
- Miti Biosystems
- MyeloPro
- OncoOne
- Origimm
- Phenaris
- Pregenerate
- Proxygen
- QUANTRO Therapeutics
- SCARLETRED
- TAmiRNA
- Thermo Fisher Scientific
- Valneva
- X4 Pharmaceuticals
- Service CompaniesService CompaniesOpen Submenu
- Business IncubatorsBusiness IncubatorsOpen Submenu
- Scientific AssociationScientific AssociationOpen Submenu
- Education
- Career
- About